
Synthesa provides AI-powered evidence synthesis services for the healthcare and pharmaceutical industries, specializing in systematic reviews, meta-analyses, and network meta-analyses. They combine deep domain expertise with cutting-edge AI, including large language models, to accelerate the identification, extraction, and synthesis of data from scientific literature. Their solutions are designed to streamline complex processes, ensuring precision, speed, and accuracy, ultimately delivering actionable, evidence-based insights faster than traditional methods. Synthesa caters to pharmaceutical and biotech companies, medical device manufacturers, medcomms agencies, CROs, and academic institutions, supporting their R&D, product validation, compliance, and market access needs.

Synthesa provides AI-powered evidence synthesis services for the healthcare and pharmaceutical industries, specializing in systematic reviews, meta-analyses, and network meta-analyses. They combine deep domain expertise with cutting-edge AI, including large language models, to accelerate the identification, extraction, and synthesis of data from scientific literature. Their solutions are designed to streamline complex processes, ensuring precision, speed, and accuracy, ultimately delivering actionable, evidence-based insights faster than traditional methods. Synthesa caters to pharmaceutical and biotech companies, medical device manufacturers, medcomms agencies, CROs, and academic institutions, supporting their R&D, product validation, compliance, and market access needs.
What they do: AI-powered evidence synthesis services (systematic reviews, meta-analyses, HTAs) for healthcare and pharma
Primary customers: Pharmaceutical & biotech companies, medtech, CROs, medcomms agencies, academic researchers
Founded: 2025
Stage / funding signal: Pre-Seed; investor listed: FJ Labs
Team size (reported): ~7 employees
Evidence synthesis and biomedical literature review for healthcare, pharmaceutical, and medical device decision-making.
2025
Data and Analytics
“FJ Labs participation in Pre-Seed”